 
 |
|
Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
Date: December 22, 2009
Client: Arena Pharmaceuticals, Inc.
Summary: San Diego, December 22, 2009 -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for lorcaserin, Arena’s internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss. The submission is based on an extensive data package from lorcaserin’s clinical development program that includes 18 clinical trials totaling 8,576 patients.
|
|
|
|
 |
|
Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening
Date: December 16, 2009
Client: Cellular Dynamics International
Summary: MADISON, Wis., Dec. 16, 2009 – Cellular Dynamics International (CDI) today announced the commercial launch of iCell™ Cardiomyocytes for use in testing of new drug candidates by the pharmaceutical industry. These human heart cells are designed to aid drug discovery and improve the predictability of drug compound efficacy and toxicity screens, weeding out ineffective and potentially toxic compounds early in the pharmaceutical pipeline process before significant time and resources have been invested.
|
|
|
|
 |
|
First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive
Date: December 16, 2009
Client: Cohera Medical, Inc.
Summary: PITTSBURGH, Dec. 16 /PRNewswire/ -- Cohera Medical Inc. today announced the treatment of the first patient in a study of its lead surgical adhesive product, TissuGlu®. Initiation of the study marks a major milestone in the company's progression of the lead product toward clinical practice.
|
|
|
|
 |
|
Data Safety Monitoring Board (DSMB) Approves Advancement to Intermediate Dose Level of PLX-PAD
Date: December 15, 2009
Client: Pluristem Therapeutics Inc.
Summary: HAIFA, ISRAEL, Dec. 15, 2009--Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT) today announced that the independent DSMB approved the advancement to the intermediate dose level of the company’s placenta derived cell therapy, PLX-PAD, in the Phase I clinical trial in Europe for the treatment of CLI, the end stage of peripheral artery disease (PAD).
|
|
|
|
|
|
Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential
Date: December 10, 2009
Client: Arena Pharmaceuticals, Inc.
Summary: SAN DIEGO, Dec 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported that positive data from a clinical trial evaluating the abuse potential of lorcaserin were presented in a poster session at the 48th Annual Meeting of the American College of Neuropsychopharmacology. Data from the trial demonstrate that the risk for abuse associated with lorcaserin is very low.
|
|
|
|
|
|
Pluristem Will Present on the Value of Placental-derived Mesenchymal Stromal Cells in Wound Healing at the 10th Annual Wound Healing: Science and Industry Conference
Date: December 10, 2009
Client: Pluristem Therapeutics Inc.
Summary: HAIFA, ISRAEL, Dec. 10, 2009--Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT) today announced that it will present at the 10th Annual Wound Healing: Science and Industry conference at the Wyndham Sugar Bay Resort and Spa in St. Thomas, U.S. Virgin Islands. William R. Prather R.Ph., M.D., senior vice president of corporate development at Pluristem, will present on the value of placental-derived mesenchymal stromal cells in wound healing at 8:10 a.m. Atlantic Standard Time, Friday, Dec. 11, 2009.
|
|
|
|
 |
|
Helix BioPharma Reports On 2009 Annual General Meeting
Date: December 9, 2009
Client: Helix BioPharma Corp.
Summary: AURORA, Ontario, Dec. 9 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: HBP; OTCQX: HXBPF) reports that at its Annual General Meeting held today, shareholders approved all of management's proposals.
|
|
|
|
|
|
Helix BioPharma Corp. Announces Fiscal Q1 2010 Results
Date: December 9, 2009
Client: Helix BioPharma Corp.
Summary: AURORA, Ontario, Dec. 9 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: HBP; OTCQX: HXBPF) today announced financial results for the first quarter ended October 31, 2009.
|
|
|
|
 |
|
Al Novak Elected Chairman of the Board of OrbusNeich Medical
Date: December 9, 2009
Client: OrbusNeich
Summary: HONG KONG, Dec. 9, 2009 – OrbusNeich today announced that Al Novak has been elected chairman of the board. Novak, 61 years old, will continue to serve as president and chief executive officer of OrbusNeich, the role that he has held since 2008. He brings over 27 years of leadership experience in the medical technology industry to the position having served as chief executive officer of Novoste Corporation and Biosense, Inc. and in marketing and financial positions with Cordis Corporation including vice president and chief financial officer. Mr. Novak was a founder of Syntheon LLC and also serves on the board of directors of Cyberonics Inc., a NASDAQ listed company.
|
|
|
|
 |
|
Delivering Medicine Directly into a Tumor
Date: December 7, 2009
Client: Burnham Institute for Medical Research
Summary: (Santa Barbara, Calif.) — Researchers at Burnham Institute for Medical Research at University of California, Santa Barbara have identified a peptide (a chain of amino acids) that specifically recognizes and penetrates cancerous tumors but not normal tissues. The peptide was also shown to deliver diagnostic particles and medicines into the tumor. This new peptide, called iRGD, could dramatically enhance both cancer detection and treatment. The work is being published December 8 in the journal Cancer Cell.
|
|
|
|
|
|
Pluristem Therapeutics Will Present on Clinical Trial Standardization and Overcoming Regulatory Hurdles at the 7th Annual Commercial Translation of Regenerative Medicine
Date: December 3, 2009
Client: Pluristem Therapeutics Inc.
Summary: HAIFA, ISRAEL, Dec. 3, 2009--Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT) today announced that it will present at the 7th Annual Commercial Translation of Regenerative Medicine at the NH Harrington Hall in London. Chaya Mazouz, vice president of clinical and regulatory affairs at Pluristem, will present on developing clinical trial standardization as a process and overcoming regulatory hurdles at 9:10 a.m. BST, Friday, Dec. 4, 2009.
|
|
|
|
 |
|
The Scientist Magazine Recognizes febit’s HybSelect Among the Winners of “Top 10 Innovations of 2009”
Date: December 2, 2009
Client: febit
Summary: LEXINGTON, Mass. and HEIDELBERG, Germany, December 2, 2009 – febit’s HybSelect has been recognized as one of the winners of the “Top 10 Innovations of 2009” by The Scientist magazine. The company’s automated sequence capture technology for high-throughput sequencing was selected due to its exceptional combinations of invention, vision and utility.
|
|
|
|
 |
|
S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders
Date: December 2, 2009
Client: S*BIO
Summary: SINGAPORE, Dec. 2 /PRNewswire/ -- S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans.
|
|
|
|
|
|
Kimmel Cancer Center of Thomas Jefferson University to Study Genomics Using febit’s Sequence Capture and microRNA Solutions
Date: December 1, 2009
Client: febit
Summary:LEXINGTON, Mass. (USA), and HEIDELBERG, Germany, December 1, 2009 – The Cancer Genomic Microarray Facility at the Kimmel Cancer Center of the Thomas Jefferson University, Philadelphia, selected febit’s Geniom® RT Analyzer to advance its biomedical research by proceeding targeted Next-Generation Sequencing (NGS), genome-wide single nucleotide polymorphism (SNP) and microRNA (miRNA) analysis.
|
|
|
|
|
|
OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent
Date: December 1, 2009
Client: OrbusNeich
Summary: Fort Lauderdale, Fla, Dec. 1, 2009 – OrbusNeich today announced the initiation of patient enrollment in the randomized clinical trial of the Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent). |
|
|
|
|
|
Industry Forms Association to Address Opportunities and Challenges of Synthetic Biology
Date: December 1, 2009
Client: febit
Summary: CAMBRIDGE, Mass., December 1, 2009 – To address the emergence of the synthetic biology industry and to promote its potential, a group of individuals and companies announced the formation of the Synthetic Biology Industry Association (SynBIA) in Cambridge, Massachusetts last week. The goal of the association is to provide a forum for individuals and commercial interests to discuss the new industry, address its opportunities and its challenges, and advocate for its development. Founding members include representatives of febit, GENEART, Ginkgo BioWorks, Biosearch Technologies and Sutro Biopharma.
|
|
|
|
|
|
Pluristem Therapeutics Completes Dosing of First Group of Patients in Europe with Placenta-Derived Cell Therapy Product PLX-PAD in Phase I Clinical Trial for Treatment of Critical Limb Ischemia (CLI)
Date: December 1, 2009
Client: Pluristem Therapeutics Inc.
Summary: HAIFA, ISRAEL, Dec. 1, 2009--Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT) today announced that it has completed dosing of the first of three dosage groups of patients in Europe with its placenta-derived cell therapy product, PLX-PAD, in a Phase I dose-escalating clinical trial for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
|
|
|
|
|
